The U.S. Food and Drug Administration (FDA ... improving overall health. The approval of Zepbound underscores the evolving landscape of OSA management, combining weight-loss benefits with improved ...

The Food and Drug Administration has approved ... Health and Lilly USA. "Zepbound is the first medication that significantly improves moderate-to-severe OSA and aids in long-term weight loss ...

which was approved for weight loss for those with obesity, or who are overweight and have a weight-related health condition, in November 2023. Although the new FDA green light doesn’t expand the ...

The approval supports evidence that GLP-1 drugs improve overall health along with weight loss. In March, the FDA approved Wegovy, from Novo Nordisk, to reduce heart disease risk. Other studies are ...

called the FDA’s approval a "promising advancement for the millions of people who suffer from this condition." "Zepbound promotes weight loss and has been shown to reduce apnea events." ...

21 (UPI) --Zepbound, the new GLP-1 weight-loss ... "Today's approval marks the first drug treatment option for certain patients with obstructive sleep apnea," said Dr. Sally Seymour of the FDA's ...

The move comes as weight-loss ... when the FDA approved Wegovy for cardiovascular disease risk reduction early in 2024,” Juliette Cubanski, a deputy director of KFF, a nonpartisan health-care ...

The Food and Drug Administration on Friday approved Eli Lilly’s weight-loss drug Zepbound to treat sleep apnea, a common but potentially serious sleep-related breathing disorder, marking it the first ...

The first medication for obstructive sleep apnea has been approved by the US Food and Drug Administration (FDA).